Toxicogenomics:a 2020 vision by Liu, Zhichao et al.
 
 
Toxicogenomics
Liu, Zhichao; Huang, Ruili; Roberts, Ruth; Tong, Weida
DOI:
10.1016/j.tips.2018.12.001
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Liu, Z, Huang, R, Roberts, R & Tong, W 2019, 'Toxicogenomics: a 2020 vision' Trends in Pharmacological
Sciences, vol. 40, no. 2, pp. 92-103. https://doi.org/10.1016/j.tips.2018.12.001
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility 27/03/2019
©2018 The Authors. Published by Elsevier Ltd.This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 13. Aug. 2019
OpinionToxicogenomics: A 2020 VisionZhichao Liu,1,* Ruili Huang,2 Ruth Roberts,3,4 and Weida Tong1,*Highlights
Together with the promotion of non-
animal testing, in vitro toxicogenomics
(TGx) may play a vital role in the next-
generation risk assessment paradigm.
A strategic shift in risk assessment
provides an unprecedented opportu-
nity for repositioning TGx in the regu-
latory setting.
As the emerging technique continues
to impact the TGx ﬁeld, novel genomic
features such as miRNAs, ncRNAs,
and circular RNAs may provide more
resolution towards better understand-
ing of the underlying mechanisms of
toxicological processes.
Advances in machine learning and arti-
ﬁcial intelligence are gaining ground for
their applicability in biomedical ﬁelds.
In the near future, these advances may
be further applied in the TGx ﬁeld to
improve predictive power.
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weida.tong@fda.hhs.gov (W. Tong).Toxicogenomics (TGx) has contributed signiﬁcantly to toxicology and now has
great potential to support moves towards animal-free approaches in regulatory
decision making. Here, we discuss in vitro TGx systems and their potential
impact on risk assessment. We raise awareness of the rapid advancement of
genomics technologies, which generates novel genomics features essential for
enhanced risk assessment. We speciﬁcally emphasize the importance of repro-
ducibility in utilizing TGx in the regulatory setting. We also highlight the role of
machine learning (particularly deep learning) in developing TGx-based predic-
tive models. Lastly, we touch on the topics of how TGx approaches could
facilitate adverse outcome pathways (AOP) development and enhance read-
across strategies to further regulatory application. Finally, we summarize cur-
rent efforts to develop TGx for risk assessment and set out remaining
challenges.
Toxicogenomics in Regulatory Application: Challenges and Opportunities
Animal models are used to assess and avoid risk to humans from exposure to potential
hazards, but their use is under constant review, especially in the light of some reports of poor
extrapolation for complex endpoints, such as hepatotoxicity and carcinogenicity. Conse-
quently, 21st century toxicology emphasizes alternative means of risk assessment and the
promotion of the 3Rs (replacement, reduction, and reﬁnement of animals in toxicology testing)
[1]. In Europe, great efforts have been made to advance the 3Rs with the aim of developing
animal-free risk assessment methodologies. To this end, several high-proﬁle programs are
underway, such as the Framework Programme 7 (FP7), Horizon 2020, and some public–
private partnerships, including Safety Evaluation Ultimately Replacing Animal Testing
(SEURAT-1) and the Innovative Medicines Initiative (IMI). Furthermore, a series of EU Legislative
directives have been developed and implemented over the past three decades, with an
emphasis on moving away from animal testing; since 2013, animal models have been pro-
hibited for testing cosmetics or household products in the EU, as well as in Israel and India [2]. In
the US, government-initiated efforts comprise advanced regulatory sciences proposed by the
US FDA [3] and Tox21 [4] [which involves four government agencies, including the Environ-
mental Protection Agency (EPA), National Center for Advancing Translational Sciences,
National Institute of Environmental Health Sciences, and the FDA] and ToxCast [5] (by the
EPA). These ongoing efforts actively advocate and promote in silico and in vitro approaches,
including toxicogenomics (TGx) (see Glossary), for prioritization and also for a potential
application in risk assessment.
TGx, as a subdiscipline of toxicology, has been successfully implemented to address critical
issues and questions in a broad spectrum of toxicology. The rapid advancement of next-
generation sequencing (NGS) technologies has gained traction in clinical application, particu-
larly in personalized cancer diagnosis and prognosis, offering great opportunities for precision
medicine. Meanwhile, the entire toxicology ﬁeld has also been impacted by the rapid develop-
ment with these advanced sequencing technologies. Equipped with innovative technologies in92 Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2 https://doi.org/10.1016/j.tips.2018.12.001
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Glossary
Adverse outcome pathways
(AOPs): a conceptual framework
connecting a molecular initiating
event and key events with outcome
and adverse effects in risk
assessment.
DrugMatrix: one of the largest
toxicogenomic reference resources,
consisting of 638 compounds tested
under microarray technology and
their corresponding pathology data in
rat, which covers 137 mechanism of
toxicity-related pathways and 50
pathological endpoints.
FAIRsharing community: a web-
based, searchable portal of three
interlinked registries, containing both
in-house and crowdsourced
manually curated descriptions of
standards, databases, and data
policies, combined with an integrated
view across all three types of
resource.
Gene Expression Omnibus (GEO):
the world’s largest functional
genomics data repository developed
by the National Center for
Biotechnology Information.
Idiosyncratic toxicity: is not dose-
dependent and unpredictable.
Idiosyncratic toxicity is caused by
drug- and patient-related risk factors.
Drug-related risk factors include
metabolism, bioactivation and
covalent binding, and the inhibition of
key cell functions. Patient-related risk
factors include genetic background,
underlying disease, age, gender,
comedications, and activation of theboth genomics and high-throughput methodologies, TGx provides an unprecedented oppor-
tunity for improved risk assessment and regulatory decision making. Moving towards the
concept of an animal-free, next-generation risk assessment paradigm, it is of great importance
to rethink and reposition TGx to meet regulatory needs.
Figure 1 summarizes some challenges and opportunities in moving from considering available
technologies to the use of TGx in the regulatory decision-making process. While the potential
uses of TGx results in the regulatory environment is multifaceted, current efforts and progress
are mainly in the area of mechanistic and predictive information. Mechanistic information can be
presented in a variety of forms, such as mode-of-action, critical toxicity related pathways, and
gene functions. Among these, advanced adverse outcome pathways (AOPs) hold the
promise to elucidate underlying toxicity mechanisms, enabling screening assay development
[6]. On the predictive side, similarly, there exists a broad range of machine learning methods.
Notably, deep learning (part of the broader family of machine learning methods based on
learning data representations as opposed to task-speciﬁc algorithms) could be a promising
approach to advance TGx. Irrespective of the approach being used and the speciﬁc application
intended, reliable and consistent reproduction of results is the prerequisite for successful
application of TGx results in the regulatory setting. Thus, it is imperative to establish and
implement a reliable and reproducible protocol for in vitro TGx studies. With the rapid advance-
ment and evolution of genomic technologies, there are signiﬁcant challenges in establishing
consistency and transferability in approaches between ﬁelds and between labs and users. In
the following sections, we will discuss some of the options and opportunities in these ﬁelds.
In Vitro TGx
As highlighted earlier, risk assessment is moving away from animal testing to alternative
methodologies. Notably, in vitro assay systems derived from animal or human tissues are
proving increasingly useful as an adjunct within the longer-term animal-based testing paradigm.
However, these in vitro approaches are challenged due to uncertainty and limited transferability
power to in vivo models [7]. Table 1 summarizes some representative cell-based in vitro models
used as a starting point for the generation of TGx data. Notably, in vitro TGx approaches are still
dominated by liver models; in the absence of a comprehensive, head-to-head comparison it
remains difﬁcult to conclude whether liver models are indeed the most informative. Also, theinnate immune system.
In vitro to in vivo extrapolation
(IVIVE): can be broadly deﬁned as
an approach extrapolating the
experimental results or observations
made in vitro to predict in vivo
phenomena qualitatively or
quantitatively.
KEGG: Kyoto Encyclopedia of
Genes and Genomes database, a
collection of data resources that
takes account of the complex
relationship among biological
pathways, diseases, and chemical
substances/drugs.
OmicsMapNet: an approach to
transform omics data to 2D images
as an input for building deep
convolutional neural network (CNN).
Open TG-GATEs: a large-scale
toxicogenomics database that stores
gene expression proﬁles, pathological
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Figure 1. The Pyramid of Toxicogenomics (TGx) towards Regulatory Decision Making. Some outstanding
questions and potential solutions for promoting TGx in respect of decision making are shown. iPSC, Induced pluripotent
stem cell.
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data, and biochemical testing results
derived from rat in vivo and in vitro
(primary rat hepatocytes, primary
human hepatocytes) exposure to 170
compounds at multiple time and
dosages points.
Phase II enzymes: phase II
enzymes oversee conjugation
reactions, which generally serve as a
detoxifying step in drug metabolism.
Phase II enzymes are mainly
transferases.
Registration, Evaluation,
Authorization and Restriction of
Chemicals (REACH): a European
Union regulation that aims to
address the production and use of
chemical substances, and their
potential impacts on both human
health and the environment.
RNA-Seq: uses next-generation
sequencing (NGS) to reveal the
presence and quantity of RNA in a
biological sample at a given moment,
which is used to analyze the
continuously changing cellular
transcriptome.
Toxicogenomics (TGx): a
subdiscipline of pharmacology that
applies genomic technologies (e.g.,
genetics, genome sequence analysis,
gene expression proﬁling,
proteomics, metabolomics, and
related approaches) to study the
adverse effects of environmental and
pharmaceutical chemicals on human
health and the environment.
Treemap approach: an information
visualization method for displaying
hierarchical data using nested ﬁgures
such as rectangles.
Xenobiotic metabolism: xenobiotic
metabolism is in charge of removing
xenobiotics from the body, consisting
of the deactivation and excretion of
xenobiotics, and happens mainly in
the liver. For example, a group of
enzymes involved in xenobiotic
metabolism is the hepatic
microsomal cytochrome P450
system.quality and utility of the different types of cells used are all inﬂuenced by multiple factors, such as
chemical properties, cell differentiation, tissue variation, measured toxicity endpoints, and
experimental protocols.
Early efforts on TGx testing system comparisons have demonstrated the complexity and
challenges imposed by the variability among cell types, gene proﬁling platforms, and measured
endpoints [8]. Often, conclusions varied due to the limited number of compounds studied and
the different types of cells and cultures. Some recent comparisons among different TGx testing
systems were conducted with large-scale TGx studies, including multiple cell cultures [9,10].
For example, Sutherland et al. [9] comprehensively assessed the concordance of drug-induced
transcriptional response in the rat, mouse liver, and cultured hepatocytes with Gene Expres-
sion Omnibus (GEO), Open TG-GATEs [11]iii and DrugMatrix. The authors suggested that
better concordance could be obtained at the coexpression network level of RNA than at
individual genes and gene-set levels. Nonetheless, most TGx studies have concluded that the
variability is mainly dependent on measured endpoints [12], implying that the selection of in vitro
TGx model system should largely be driven by the type of perturbations being studied.
It is valuable to highlight that some novel in vitro models, such as 3D cultures, stem cells,
organoids, and physiologically based pharmacokinetic modeling have great potential to
improve the stability of in vitro assay systems (Table 1) [13,14]. Unfortunately, the evaluation
of the use of these novel models in TGx is limited by the number of compounds tested so far.
Although the future of these types of in vitro TGx are promising and could play a critical role in
regulatory decision making, comprehensive and comparative analyses with study designs
across various novel models need to be conducted to warrant their utility and deﬁne the
applications where they are ﬁt-for-purpose [15].
Technology Advancements and Their Impact on TGx
Technology advancements make TGx approaches increasingly powerful and cost effective.
The interplay between technology evolution and toxicology application continues to drive TGx
into high-throughput applications for mechanistic investigation and multigene biomarker dis-
covery. There is a steep learning curve between novel technology to real-world application; the
key challenge to overcome in order to take full advantage of these novel technologies is in
choosing ﬁt-for-purpose approaches in balancing cost and effect.
Microarray versus RNA-Seq
Rapid technological advancement, along with a sharp decline in cost, has placed NGS at
the center stage of genomics research in the broad biomedical ﬁeld [16]. This raises the
question as to whether the TGx ﬁeld is ready to migrate from microarray to NGS-based
approaches. Currently, the answer remains ambiguous and complex. On the one hand,
microarray technology has a proven track record spanning the past two decades with a
vast amount of accumulated microarray data that is publicly available. On the other hand,
RNA-Seq has demonstrated advantages in detecting low-expressed genes compared
with microarrays [12]. So, can we ‘bridge’ by applying biomarkers generated from micro-
array platforms to data derived from RNA-Seq? Since the technology is rapidly evolving,
this bridging challenge will be repeated in each iteration. Thus, it would be valuable to focus
on understanding the potential transferability of biomarkers from old technologies to new
ones and vice versa. Via this route, the predictive sustainability across evolved technolo-
gies can be understood and the rich data sets accumulated from past investment can be
leveraged.94 Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2
Table 1. Examples of In Vitro Models Used in Toxicogenomics
Model Organ Species Advantages Disadvantages Refs.
Tissue slices Liver Rat/mouse/
human
 Liver structure is maintained with all cell types
 Good correlation with in vivo regarding
xenobiotic metabolism and zone-speciﬁc
cytochrome activity
 Phase II enzymes, gluconeogenesis, and
albumin production could be retained with 20–
96 hours
 Necrosis occurs after 48–72 hours
 Metabolic enzyme levels decreased after
6 72 hours
 Drug metabolism and intrinsic clearance
rates are lower than primary hepatocytes
[52]
Primary hepatocytes Liver/
kidney
Rat/mouse/
human
 Functional activities could be maintained for
24–72 hours
 Ideal for assessing the interspecies and
interindividual differences in metabolism
 Suitable for enzyme induction and inhibition
studies
 Hepatocyte de-differentiation changes
function, gene expression, cell morphology
 Microenvironment lost
 Cytochrome P450 expression decline
quickly after 24–48 hours
[53]
Immortalized cell
lines (e.g., HepaRG
and HepG2)
Liver Rat/mouse/
human
 High proliferative capacity and stable
karyotype
 Expression level of most liver functions and
phase I/II enzymes can be retained in a lower
percentage than primary hepatocytes
 Individual donor phenotype can be retained
 Limited predictive power of toxicity is
retained in population level
[54]
Three-dimensional
culture systems
Liver Rat/mouse/
human
 Hepatocyte functions are improved
compared with monolayer culture
 Cell types are retained and longevity is
extended
 Good correlation with in vivo toxicity
 Cell interaction, morphology is more stable
 Limited successful co-culture (mainly with
ﬁbroblasts cells)
 Standard culture construction protocol is
needed
 Not fully high throughput
[55]
Embryonic stem cells Liver/
cardio/brain
Rat/mouse/
human
 Easily studied with most established omics
techniques
 Deﬁne phenotypes for many organ toxicity
 Developmental toxicity
 Lower expression for metabolism-related
genes
 Not ﬁt for long-term experiments
 Bioengineering required
[51]
Induced pluripotent
stem
cells
Liver/
cardio/brain
Rat/mouse/
human
 Individual variability can be assessed
 Idiosyncratic toxicity
 Deﬁned phenotype (multiple disease models)
 Easily studied with most established omics
techniques
 Bioengineering required
 Lack of robust and reproducible
differentiation protocols
 Loss of the functionality of native
hepatocytes
 Lower expression level of metabolism-
related genes
[56]
Organoids Multiple organs Rat/mouse/
rat and other
species
 Limited amounts of starting material required
 Can be propagated for a long time
 Can be derived from multiple tissues and
species
 Good preservation of physiological features
 The native microenvironment of derived
tissues could not be well maintained
 Unable to mimic in vivo growth factor
 Limited use in modeling inﬂammatory
responses of tissues
[57]The Choice of Genomic Methods in TGx Research
NGS offers several beneﬁts beyond gene expression proﬁling, as most TGx studies are more
focused than NGS. For example, NGS has been widely used in detecting novel genetic variants,
including complex structural variants such as gene fusion, rare mutation, short and long
noncoding RNAs (ncRNAs) [17], and circular RNAs [18] (Figure 2). These novel genomic
features are expected to advance the role of TGx in a broad range of toxicology studies.
Despite the signiﬁcant decline in the cost of NGS, it has remained economically challenging to
screen vast numbers of industrial and environmental chemicals with the current NGS technol-
ogies. Thus, researchers still need to carefully weigh the options of choosing one technology
over others by considering cost, purpose, and speed.Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2 95
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• Interpretaon of the novel
gene elements and events 
• Knowledge base development
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• Novel data analysis methods 
• Data integraon approaches
Figure 2. Application of Novel Genomics Technologies in Toxicogenomics (TGx). Some novel genomics
technologies such as RNA-Seq and TempO-SeqTM have been well established in the TGx ﬁeld. The novel genomics
features beyond mRNA, including miRNA, noncoding RNA, and circular RNAs, provided extra resolution for identifying and
understanding the underlying mechanism of toxicities. Bioinformatics approaches, including data integration, systems
biology, and the network, could serve as a bridge to facilitate the utilization of novel genomics technologies in TGx.Some novelapproaches developed and applied in the TGx ﬁeld are fast,affordable,and applicable
to risk assessment. For example, BioSpyder Technologies has developed a novel product for
targeted sequencing called TempO-SeqTM, a gene expression proﬁling tool designed to monitor
hundreds to thousands of genes at once in high throughput at an extremely lower cost per sample.
Furthermore, the technology is very sample friendly, accepting diverse samples, such as formalin-
ﬁxed parafﬁn-embedded tissues and single cells from different species, with minimal sample input
(i.e., 10 pg) [19]. Another example is the National Institute of Health Library of Integrated Network-
Based Cellular Signatures (LINCS) 1000 project [20], which aims to provide a cost-effective panel-
based method proﬁling 1000 landmark genes that can recapitulate the biology that otherwise
needs to be assessed at the whole-genome scale [21]. Based on a similar concept, Tox21
developed the S1500 gene panel, which is scheduled to screen approximately 10 000 chemicals,
including most drugs [22].
Beyond mRNA
Advances ingenomicsandbioengineeringtechnologyhaveprovidedunprecedentedopportunities
to identify different genomic features other than mRNAs [23]. These novel components have been
demonstrated to have diverse roles in biological processes and have expanded our understanding
of the underlying mechanism of toxicity (Figure 2). To advance the utility of these novel gene
elements in regulatory toxicology, the followingshould be addressed: (i) determine the roles of novel
genomic features in toxicology and the extent to which they are ﬁt-for-purpose in assessing toxicity;
(ii) develop state-of-art data analysis strategies for generating robust and reproducible measures of
these new features; and (iii) integrate various molecular events with associated phenotypic out-
comes to decipher the gene regulatory complex essential to the expression of toxicity.
Efforts have been made to link the different genetic elements to phenotypes in TGx ﬁeld [24]. For
example, miRNAs are small ncRNAs that have been demonstrated as one of the most stable96 Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2
RNA types and are conserved across many species. The expression of miRNAs tends to be
cell-type speciﬁc, which allows the development of bioﬂuid-based miRNA detection assays that
work as a ‘liquid biopsy’ to carry out fast and noninvasive early detection of toxicity [25]. Besides
miRNAs, other ncRNAs have also been identiﬁed and linked to many biological processes
through diverse mechanisms [26]. Furthermore, some integrative approaches, such as data
fusion, systems biology, and network analysis have been developed to incorporate multiple
genetic elements for risk assessment [27]. For example, Nan et al. [28] uncovered the
regulatory interactions among ncRNA, circular RNA, and miRNA for lead-induced neurotoxicity
and further veriﬁed these results with dual luciferase reporter gene assay.
Reproducibility
Reproducibility is the most important hallmark of science [29]. Concerns have been raised on
the reproducibility of genomics technology due to the complex nature and aspects regarding
cell types, genomics platforms, data analysis methodologies, and an inherent tendency to
variability both within and between different laboratories involved in testing and validation
(Figure 3). Therefore, a critical evaluation must be carried out on the reproducibility of TGx
signatures and their transferability in the biological context [30] (Box 1).
The typical TGx study is designed to determine differentially expressed genes (DEGs) by
comparing the treated condition with a control, followed by biological interpretation (e.g.,
pathways and gene functions) to understand the underlying toxicity mechanism of the treat-
ment. DEGs are extremely sensitive to study design, including the animal strain and batch, cell
culture methodologies, treatment protocol, and measured endpoints [12]. This highlights thatFigure 3. Key Challenges of Reproducibility in Toxicogenomics. The reproducibility of toxicogenomics include
both biological and technical sides. The data are generated from different cell lines in various labs with different
technologies. The repeatability and reproducibility necessities have different inﬂuential factors including cell types,
genomics platforms, and data analysis. cirRNA, Circular RNA; ncRNA, noncoding RNA.
Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2 97
Box 1. Key Considerations of TGx in a Regulatory Setting
Reproducibility: best practice in data analysis is required to ensure the reproducibility of results in TGx. To ﬁll the gap,
Consortia such as MicroArray/Sequencing Quality Control (MAQC and SEQC) are driving the reproducibility of
transcriptional measurement. Some best-practices for TGx data analysis have been suggested: (i) the differentially
expressed genes (DEGs) calculated by fold change (1.5) with a P value cutoff (0.05) are suggested for use in
downstream pathway or gene ontology analysis; (ii) the model performance mainly depended on the complexity of
endpoints and team proﬁciency rather than machine learning algorithms; and (iii) the cross-platform concordance
regarding DEGs was correlated with treatment effect, the complexity of biological mechanisms, and transcript
abundance. The RNA-Seq outperformed microarray due to low-abundance transcripts, which means the similar
performance could be generated from both RNA-Seq and microarray platform when limiting the DEGs in the high
expression level [32].
Adverse outcome pathways (AOPs): AOPs have been depicted as biological dominos integrating molecules, gene
activities, and causal adverse outcomes in sequence. TGx is an important resource to seamlessly link the information
among the AOP components and facilitate assembling knowledge. TGx has been adopted for developing organ
toxicity-related AOP, such as neurotoxicity [58] and fatty liver diseases [45]. Furthermore, the Organization for Economic
Cooperation and Development established AOP development under the oversight of its Extended Advisory Group on
Molecular Screening and Toxicogenomics (EAGMST), which aims to develop guidance detailing internationally
accepted approaches for describing and documenting AOPs for the potential regulatory application.
Read-Across: read-across assumes that two ‘similar’ compounds are likely to share a similar toxicity proﬁle. Currently,
the main emphasis is on structural similarity. However, diverse biological data for compounds of interest have been
generated and become available. These biological data, including TGx data, could be utilized to proﬁle the biological
ﬁngerprint of a chemical. If the two chemicals have similar biological proﬁles, they have a similar adverse outcome.
Biological-based read-across could be a complement to structure-based read-across. Some case reports of biological-
based read-across have been described for various complex toxicity endpoints, such as estrogenic endocrine
disruption [47].the recording of methods or protocols in TGx is essential for a result to be reproduced by
others. Therefore, the community has been discussing the value of incorporating good
laboratory practices (GLPs) into TGx. Some initial efforts, such as the Organization for Eco-
nomic Co-operation and Development, have begun to develop a GLP standard for the conduct
of TGx studies in screening compounds for toxicity detection. Even with a standardized and
GLP-like protocol, DEGs could still vary signiﬁcantly with the choice of data processing and
statistical methods. This so-called ‘computational reproducibility’ issue poses a speciﬁc and
signiﬁcant challenge to TGx and to the genomics ﬁeld in general. It is unlikely that there exists a
single analysis method that is universally correct for every TGx study and every gene measured
in the study. However, a general rule can be followed, as suggested by the FDA-led MicroArray
Quality Control (MAQC) consortium, to determine a reproducible DEG proﬁle: ranking the genes
by fold-change by comparing the treated with the control condition, followed by removing these
genes with poor statistics (measured by a nonstringent P value) [31]. The MAQC consortium
further demonstrated that, with this simple rule, a reproducible DEG proﬁle was readily achieved
across different microarray platforms for the example samples tested [32].
TGx, just like genomics applied in other ﬁelds, involves substantial computational approaches
to analyze data and visualize/present the results. TGx can learn from other ﬁelds, such as the
FAIRsharing community, to develop a strategy to reproduce the key ﬁgures and results from
published TGx studies [33]. Several journals, such as Scientiﬁc Data and GigaScience, aim to
describe scientiﬁcally valuable datasets and research that advances the sharing and reuse of
scientiﬁc data. Moreover, technology such as blockchain, that aims to create incorruptible data
trails and securely record decisions, may play an important role in improving reproducibility in
TGx [34]. In addition, the scientiﬁc community has pushed the ‘open science’ concept to
enhance data transparency and reproducible science. Some public data and code98 Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2
repositories, such as Github, have been developed, facilitating data and code share, and
communication among researchers.
Machine Learning and Predictive Models
Machine learning has been widely used in the genomics and genetics [35], and it has also
enabled TGx to place toxicology on a more predictive footing. Artiﬁcial intelligence (AI),
including machine learning, has been evaluated in the regulatory setting to facilitate digital
health criteria establishment [33]. Such a rapid advancement from research to the regulatory
application for AI has been largely encouraged by the success of deep learning in a broad
range of biomedical research [36]. As more and more TGx data is generated and becomes
available in the near future, AI, particularly deep learning, will play an increasing role in
toxicology, speciﬁcally for TGx [37]. However, the nature of toxicology studies and the
inherent complexity in a TGx study design poses many challenges in developing a meaningful
and reliable TGx-based predictive model [38] (Box 2). Firstly, the sample size is usually small in
TGx. Hence, it is difﬁcult to assess whether a predictive model developed based on a limited
number of samples could well represent a broad space of measured endpoints. Secondly, the
interpretation of such a predictive model is difﬁcult. A lot of models have good prediction
performance but the features (e.g., gene signatures) employed in the models are hard to link
to the existing knowledge of toxicity endpoints. Thirdly, it is difﬁcult to take the entire
complexity of a TGx experiment into consideration in predictive model development. For
example, many TGx experiments were carried out with multiple times and doses. Therefore,
not all of the machine learning methodologies are capable of incorporating these important
toxicology features into the predictive modeling framework. Nonetheless, several approaches
have been explored, and some of them could be important for the future development and
application of deep learning in TGx [33].
Transcriptional Proﬁling and Image Analysis
One of the most important or appreciated applications of deep learning is for image recognition
and classiﬁcation. Deep convolutional neural networks (CNN) is one of the most successfulBox 2. Machine Learning/AI in Toxicogenomics
AI is when a machine is trained to think and act like a human. Machine learning is a ﬁeld of AI that uses statistical
techniques to give computer systems the ability to ‘learn’ from data, without being explicitly programmed. Deep learning
goes beyond machine learning and uses algorithms inspired by the structure and function of the brain (so-called artiﬁcial
neural networks) to reveal hidden relationships between experimental observations and causal biological endpoints.
Learning can be supervised (where each example is a pair of an input and desired output) or unsupervised (where the AI
system is presented with uncategorized data).
Machine learning has been used since the inception of TGx to assist in data manipulation and interpretation. However,
recent advancements in AI and especially deep learning provide new opportunities to develop biomarkers with
enhanced performance and predictive capability. For example, AI approaches could assist with challenges such as
overcoming small sample sizes in TGx studies, integrating multiple gene proﬁles from different cell lines, and in
transferring transcriptional proﬁles to images via the biological relationship between genes. Consequently, deep learning
combined with TGx offers new ways to predict complex toxicological endpoints, such as nongenotoxic carcinogenicity,
alongside conventional approaches, such as early biomarker research and mechanistic analyses.
A key consideration in using predictive TGx models in the regulatory setting is to deﬁne context of use both in terms of
the scope of application and the speciﬁc roles that TGx models could play in regulatory decision making. Alongside this
scope, there are questions to be addressed, such as (i) Biological plausibility: is the gene signature in the model
consistent with existing knowledge? (ii) Biological reliability: does the gene signature cross-validate with other methods
such as real-time PCR? (iii) Statistical performance: which statistical criterion best deﬁnes the reliability of the model? (iv)
Reproducibility: what degree of reproducibility is required?
Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2 99
methodologies, since it can achieve high accuracy by emulating the behavior of optic nerves in
living creatures. CNN uses mathematical ﬁlters to correlate image pixel values with neighboring
pixel values to classify and interpret images [39]. A similar concept can be applied to TGx by
treating a transcriptional proﬁle in the same way as an image without information loss.
Speciﬁcally, analog proximity to measure gene–gene relationship can be established to
transform the 1D gene expression proﬁles to 2D images. Some initial attempts have been
reported by using pathways, gene ontology structure with distance measure strategies, to
reorganize transcriptional proﬁles to images for deep CNN. For example, Ma and Zhang [40]
proposed an OmicsMapNet strategy to rearrange 1D transcriptional proﬁling to the 2D image
for deep CNN model development, where the transcriptional proﬁling was mapped to the
KEGG pathway and then turned into an image with a treemap approach.
Overcoming the Small Sample Size in TGx Studies through Transfer Learning
The central concept of transfer learning is to assume that the knowledge learned from one
dataset with abundant information can be transferred to learn from a new dataset with
limited information. This concept is speciﬁcally relevant in TGx studies where the sample
size is always limited, posing a challenge to making reliable conclusions. Transfer learning is
widely applied in image analysis [41] and automatic speech recognition [42], but has not
been investigated in TGx. Many large genomics datasets such as GEO, Open TG-GATEs,
and DrugMatrix have been published in the past decades and can be used as transfer
learning to improve the predictive ability of TGx models with small data sets. For example,
Chen et al. [43] developed a multitask multilayer feedforward neural network to inference
the gene expression by using LINCS 1000, Genotype-Tissue Expression (GTEx) data and
1000 Genomes expression data, yielding a lower error rate than state-of-art machine
learning algorithms [43].
Unsupervised Learning
Unsupervised learning such as principle component analysis (PCA) is focused on the discovery
of natural groupings of subjects (or samples) based on the data itself (e.g., gene expression
data from microarrays). This method is of particular relevance in TGx applications since it is
always a challenge to deﬁne a phenotypic outcome and its association with gene expression
changes. Therefore, unsupervised learning like PCA has been extensively used in TGx,
particularly when dealing with a TGx experiment involving multiple doses and time points.
For example, PCA was employed to choose the most representative time/dose condition in
TG-GATEs data [44]. Unsupervised learning in a deep learning framework has brought many
opportunities for enhanced knowledge discovery in TGx. One interesting deep learning frame-
work has been proposed to aggregate the genomics data from different experimental con-
ditions for information extraction. This approach has been successfully applied to compare and
cluster genomics data of Pseudomonas aeruginosa from different experiments conducted in
different media conditions [36]. Some TGx related questions that could potentially beneﬁt from
this approach include: (i) in vitro to in vivo extrapolation (IVIVE), (ii) utilization of big genomics
data from immortal cells to enhance toxicity prediction, and (iii) elimination of the cell culture
discrepancy for integrative model development.
The Role of TGx in Developing AOPs
Risk assessment of chemical exposure is mostly based on understanding the underlying
mechanism of exposure and its relevance to human health. To facilitate this line of research,
the concept of AOPs has been established; this provides a conceptual framework to link
chemical exposure to adverse outcome or key event responses at the cellular, organ, or
organism levels via molecular initiating events and perturbation pathways. To date, a total of100 Trends in Pharmacological Sciences, February 2019, Vol. 40, No. 2
Outstanding Questions
How can we establish the standards in
regulatory oversight of in vitro toxico-
genomics (TGx) for next-generation
risk assessment?
How can we systematically integrate
the multiple genomics features to
enable an augmented elucidation of
complex toxicity outcome?
How can we enhance the reproducibil-
ity of TGx results towards more robust
and reliable results for regulatory
application?
How do we choose the correct ‘ﬁt-for-
purpose’ deep learning approaches to
improve predictive power in TGx?234 AOPs have been reported that correspond to 1764 key events. AOPs have been actively
studied to address different toxicity endpoints, such as drug-induced liver injury, liver carcino-
genicity, and neurotoxicity. Curation of an AOP concept requires tremendous knowledge and is
time-consuming. Accumulative TGx data proﬁles could accelerate the AOP concept generation
for community effort to verify the hypotheses (Box 1). These resources can be integrated with
the large publicly available TGx datasets, such as Open TG-GATEs [11] and DrugMatrix, to
develop in silico AOP concepts. For example, Bell et al. [45] incorporated Open TG-GATEs data
sets, ToxCast in vitro assays, and rat protein–protein interactions in the Reactome database to
identify computationally predicted AOP (cpAOP) scaffolds. The cpAOP can serve as a starting
point for domain experts to accelerate the AOP development.
Read-Across with TGx
Read-across assumes that two ‘similar’ compounds are likely to share a similar toxicity proﬁle
[46]. Read-across has been actively promoted in risk assessment of chemical exposure by
offering a route to ‘reﬁne, reduce and replace’ animal use in Registration, Evaluation,
Authorization and Restriction of Chemicals (REACH) [47]. For example, the Research
Institute for Fragrance Materials has adopted read-across for assessing the risks of 80% of
fragrance ingredients. Conventional read-across has mainly relied on chemical structure
similarity [47], which has met with challenges since the chemistry space usually cannot
represent the complexity of a biological process. A lot of false positive results were generated
by chemical structure-based read-across, which lacks consensus with external evidence to
substantiate a read-across for a given endpoint such as reproductive and development toxicity
[48].
With the help of ‘big data’ and omics proﬁles, the performance of read-across can be improved.
Accumulative TGx data sets can be employed to establish the similarity for projecting the
shared toxicities proﬁles (Box 1). Some TGx applications, such as DrugMatrix and LINCS 1000,
allows users to compare the measured compound with a huge number of tested compounds at
the transcriptomic levels. Furthermore, a consensus similarity approach (where similarities are
aggregated from different biological data proﬁles) could further enhance the reliability and
reproducibility of read-across. For example, Zhu et al. [46] conducted a read-across using
biological data, including TGx data, for assessing acute toxicity within the REACH program and
extrapolation between in vitro and short-term in vivo repeated dose studies with stem cells.
Concluding Remarks and Future Perspectives
The rapid growth of genomics techniques has dramatically extended the impact and reach of
TGx. However, challenges in experimental design, statistical interpretation, and reproducibility
need to be addressed before TGx can realize its full potential (see Outstanding Questions).
There are growing calls to drive more reproducibility in sciences, avoiding some wildly optimistic
and misleading conclusions [29]. The Massive Analysis and QC Society, derived from the FDA-
led consortium activities, aims to communicate, promote, and advance reproducible science
principles and quality control for analysis of massive data generated from the existing and
emerging technologies in solving biological, health, and medical problems [30]. Besides
technical reproducibility, the dimension of reproducible sciences in TGx also includes under-
standing the TGx ﬁndings and how the TGx results correlate with toxicity in humans. It is
expected that more benchmark TGx data will be generated under different platforms, cell types,
and cultures to facilitate an evaluation and robust conclusion generation.
Accumulative TGx data ﬂooding into the community has accelerated the molecular under-
standing of toxicity and enhanced predictive capability. Furthermore, some emergingTrends in Pharmacological Sciences, February 2019, Vol. 40, No. 2 101
technologies, including organ-on-a-chip [49], 3D-printed tissues [50], and nanoparticle tech-
niques [51], are used increasingly in toxicology. Accordingly, novel methodologies to model,
integrate, and mine these valuable resources are urgently needed. Some systems biology and
network approaches are promising tools for TGx data proﬁling and uncovering the complex
regulation among different gene elements. Furthermore, novel machine learning algorithms,
such as deep learning, may produce more accurate and robust prediction results from TGx
studies. Importantly, efforts are needed to consolidate and link the accumulative TGx ﬁndings to
create information-rich tools and networks for enabling data standardization, consistency, and
maintenance.
TGx has gone through a series of peaks since its inception. Now is the right time to rethink and
reevaluate TGx technology as a driver to move away from in vivo data to new approaches in
regulatory decision making. In the face of strategic shifts in the risk assessment paradigm, TGx
could play an important role and potentially be widely applied in support of regulatory strategy.
Signiﬁcantly, despite the complexity and challenging nature of TGx, the discipline has exceeded
expectations of utility in prediction. Here, we have summarized the challenges and oppor-
tunities presented by TGx from a data science perspective to stimulate community efforts for
further evaluation and to better position TGx in the regulatory setting.
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